Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFXI.L Regulatory News (FXI)

  • There is currently no data for FXI

Trading Update

7 Oct 2013 07:00

RNS Number : 8126P
Fusionex International PLC
07 October 2013
 



For Immediate Release

7 October 2013

 

 

 

Fusionex International plc

("Fusionex", "the Company" or "the Group")

 

Trading Update

 

Fusionex, an award-winning and market leading international software provider specialising in Business Intelligence, Analytics and Big Data, is pleased to provide the following trading update in advance of its results for the year ended 30 September 2013, which will be announced on or before 31 Jan 2014.

 

During the period, management has made good progress delivering the Group's stated growth strategy of broadening Fusionex's geographical reach and continuing to develop its Big Data offerings and capabilities. The Company's business pipeline remains strong with the team continuing to experience significant demand for its products. This on-going demand is further strengthened by increased awareness of Fusionex's brand and product offerings, particularly across Asia Pacific, where Fusionex recently won Microsoft's Asia Pacific Award for Business Intelligence.

 

Fusionex has also secured its first client in Hong Kong, a key business hub and gateway to North Asia (including China) and a region where management believes strong product demand continues to exist. The Group has built a steady sales pipeline over the last few months in Hong Kong (which covers Northern Asia), and Management is therefore confident that it will progressively win more new business from Hong Kong and China.

 

Fusionex's flagship Big Data product, GIANT, is now in advanced stages of testing. Once launched, GIANT will be able to be deployed to either cloud, on-premise or hybrid environments. Fusionex has conducted a number of paid pilots with clients, and full product launch continues to be targeted before the end of calendar year 2013.

 

In addition Fusionex would like to notify shareholders the Company is now subject to the UK Takeover Code. As of 30 September 2013, all UK, Channel Island and Isle of Man incorporated public companies which have securities admitted to trading on AIM will be subject to the Code, irrespective of their place of central management and control.

Management remains confident that a combination of the Group's strong market traction within the Asia Pacific region, significant sales momentum and on-going investment in sales and development teams will continue to generate exciting growth in the medium and long term.

 

The board anticipates that the revenue as well as profit achieved for the full year results for the year ending 30 September will be at least in line with market expectations.

 

 

For further details:

Fusionex

Ivan Teh, Chief Executive Officer

Yuen Choong Lai, Chief Financial Officer

 

Through Buchanan

 

Panmure Gordon

Fred Walsh, Grishma Patel, Ben Roberts (Investment Banking)

Tom Nicholson, Charles Leigh-Pemberton (Corporate Broking)

020 7886 2500

Buchanan

Jeremy Garcia, Gabriella Clinkard

www.buchanan.uk.com

020 7466 5000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUSOVROBARRAA
Date   Source Headline
26th Jun 20177:00 amRNSContract Win
23rd Jun 20177:00 amRNSMatched Bargain Facility
21st Jun 20177:30 amRNSSuspension - Fusionex International plc
20th Jun 20172:05 pmRNSSecond Price Monitoring Extn
20th Jun 20172:00 pmRNSPrice Monitoring Extension
20th Jun 201711:04 amRNSNotification of Major Interest in Shares
20th Jun 20177:00 amRNSResignation of Nomad and Broker
19th Jun 201711:05 amRNSSecond Price Monitoring Extn
19th Jun 201711:00 amRNSPrice Monitoring Extension
15th Jun 201712:35 pmRNSResult of EGM
2nd Jun 20177:00 amRNSLaunch of GIANT 2017
30th May 20172:05 pmRNSSecond Price Monitoring Extn
30th May 20172:00 pmRNSPrice Monitoring Extension
30th May 20179:05 amRNSSecond Price Monitoring Extn
30th May 20179:00 amRNSPrice Monitoring Extension
30th May 20177:00 amRNSResignation of Joint Broker and Director
26th May 20175:30 pmRNSProposed cancellation of trading on AIM
15th May 20177:00 amRNSFinancial Services contract win
13th Apr 201710:30 amRNSNotification of Board Composition
11th Apr 20177:00 amRNSMajor Contract Win with Galaxy Entertainment Group
7th Apr 20177:00 amRNSContract win with healthcare system provider
4th Apr 20177:00 amRNSUpgraded GIANT 2017 platform contract win
31st Mar 20175:55 pmRNSResult of AGM
30th Mar 20175:10 pmRNSNotification of Major Interest in Shares
16th Mar 20177:00 amRNSPosting of Annual Report
15th Mar 20177:00 amRNSPreliminary Results
10th Feb 20177:00 amRNSAppointment of Nomad and Joint Broker
22nd Dec 201610:45 amRNSEstablishment of Employee Benefit Trust
12th Dec 20167:00 amRNSGIANT 2016 contract win with major Asian bank
24th Oct 20167:00 amRNSTrading Update
5th Oct 20167:00 amRNSNew Deal with Global Media Conglomerate
6th Sep 20167:00 amRNSAppointment of Joint Broker
2nd Sep 20167:00 amRNSFusionex signs agreement with Bursa Malaysia
12th Jul 20167:00 amRNSMajor GIANT 2016 win in the Philippines
4th Jul 20167:00 amRNSNew GIANT 2016 platform secures first contract
28th Jun 20167:00 amRNSLaunch of Fusionex GIANT 2016
1st Jun 20167:58 amRNSInterim Results
1st Jun 20167:00 amRNSInterim Results
17th May 20167:00 amRNSNotification of Interim Results
18th Apr 20167:00 amRNSTrading Update
16th Mar 20167:00 amRNSDividend Declaration
11th Mar 201611:30 amRNSResult of AGM
2nd Mar 20164:02 pmRNSStrategic Alliance with Cloudera
25th Feb 20168:30 amRNSPosting of Annual Report
5th Feb 20162:44 pmRNSDirector's Share Dealing
3rd Feb 20167:00 amRNSDirector's Share Dealing
1st Feb 20167:00 amRNSNotification of Major Interest in Shares
29th Jan 20164:40 pmRNSSecond Price Monitoring Extn
29th Jan 20164:37 pmRNSPrice Monitoring Extension
28th Jan 20164:57 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.